Cargando…
Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler
BACKGROUND: Intramuscular (L-)epinephrine is used as self-medication for serious hypersensitivity reactions. Inhalative administration has the theoretical advantage of a more rapid absorption and better controllability. OBJECTIVES: The current trial was conducted to explore pharmacokinetics and phar...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3651817/ https://www.ncbi.nlm.nih.gov/pubmed/23292159 http://dx.doi.org/10.1007/s00228-012-1465-5 |
_version_ | 1782269240584175616 |
---|---|
author | Breuer, C. Wachall, B. Gerbeth, K. Abdel-Tawab, M. Fuhr, U. |
author_facet | Breuer, C. Wachall, B. Gerbeth, K. Abdel-Tawab, M. Fuhr, U. |
author_sort | Breuer, C. |
collection | PubMed |
description | BACKGROUND: Intramuscular (L-)epinephrine is used as self-medication for serious hypersensitivity reactions. Inhalative administration has the theoretical advantage of a more rapid absorption and better controllability. OBJECTIVES: The current trial was conducted to explore pharmacokinetics and pharmacodynamics of two nebulized inhalative epinephrine doses (4 mg and 8 mg in aqueous solution) using a mobile pocket inhaler relative to intramuscular administration (0.3 mg) and placebo. METHODS: This randomized, open-label, change-over pilot study involved eight young healthy men and women. Noncompartmental pharmacokinetic and pharmacodynamic parameters were calculated from epinephrine plasma concentrations and hemodynamic parameters. RESULTS: Mean exposure to epinephrine decreased from the 8 mg dose to the 4 mg inhalative dose, and further with the 0.3 mg intramuscular dose, with active treatments showing significantly higher concentrations than placebo (geometric mean area under the curve AUC(0-t(last)) values: 282, 236, 204 and 81.6 hr*ng/L). Maximal concentrations were reached within approximately 15 min for all active treatments. Epinephrine effects for inhalative administrations on heart rates were significantly higher than those for the intramuscular or placebo administration, while no excessive effects occurred. Pronounced overall variability prohibited a definite assessment of relative bioavailability between treatments. However, results indicated that epinephrine concentrations obtained following the 8 mg inhalative dose were not inferior to those after 0.3 mg i.m. CONCLUSIONS: A relevant fraction of moist inhalation epinephrine doses is absorbed and mediates systemic effects. This suggests that administration of epinephrine via a suitable pocket inhaler device may be beneficial in ambulatory emergency treatment of systemic hypersensitivity reactions. EudraCT number: 2010-021493-11 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00228-012-1465-5) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-3651817 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-36518172013-05-13 Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler Breuer, C. Wachall, B. Gerbeth, K. Abdel-Tawab, M. Fuhr, U. Eur J Clin Pharmacol Pharmacokinetics and Disposition BACKGROUND: Intramuscular (L-)epinephrine is used as self-medication for serious hypersensitivity reactions. Inhalative administration has the theoretical advantage of a more rapid absorption and better controllability. OBJECTIVES: The current trial was conducted to explore pharmacokinetics and pharmacodynamics of two nebulized inhalative epinephrine doses (4 mg and 8 mg in aqueous solution) using a mobile pocket inhaler relative to intramuscular administration (0.3 mg) and placebo. METHODS: This randomized, open-label, change-over pilot study involved eight young healthy men and women. Noncompartmental pharmacokinetic and pharmacodynamic parameters were calculated from epinephrine plasma concentrations and hemodynamic parameters. RESULTS: Mean exposure to epinephrine decreased from the 8 mg dose to the 4 mg inhalative dose, and further with the 0.3 mg intramuscular dose, with active treatments showing significantly higher concentrations than placebo (geometric mean area under the curve AUC(0-t(last)) values: 282, 236, 204 and 81.6 hr*ng/L). Maximal concentrations were reached within approximately 15 min for all active treatments. Epinephrine effects for inhalative administrations on heart rates were significantly higher than those for the intramuscular or placebo administration, while no excessive effects occurred. Pronounced overall variability prohibited a definite assessment of relative bioavailability between treatments. However, results indicated that epinephrine concentrations obtained following the 8 mg inhalative dose were not inferior to those after 0.3 mg i.m. CONCLUSIONS: A relevant fraction of moist inhalation epinephrine doses is absorbed and mediates systemic effects. This suggests that administration of epinephrine via a suitable pocket inhaler device may be beneficial in ambulatory emergency treatment of systemic hypersensitivity reactions. EudraCT number: 2010-021493-11 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00228-012-1465-5) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2013-01-05 2013 /pmc/articles/PMC3651817/ /pubmed/23292159 http://dx.doi.org/10.1007/s00228-012-1465-5 Text en © The Author(s) 2012 https://creativecommons.org/licenses/by-nc/2.0/ Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Pharmacokinetics and Disposition Breuer, C. Wachall, B. Gerbeth, K. Abdel-Tawab, M. Fuhr, U. Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler |
title | Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler |
title_full | Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler |
title_fullStr | Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler |
title_full_unstemmed | Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler |
title_short | Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler |
title_sort | pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler |
topic | Pharmacokinetics and Disposition |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3651817/ https://www.ncbi.nlm.nih.gov/pubmed/23292159 http://dx.doi.org/10.1007/s00228-012-1465-5 |
work_keys_str_mv | AT breuerc pharmacokineticsandpharmacodynamicsofmoistinhalationepinephrineusingamobileinhaler AT wachallb pharmacokineticsandpharmacodynamicsofmoistinhalationepinephrineusingamobileinhaler AT gerbethk pharmacokineticsandpharmacodynamicsofmoistinhalationepinephrineusingamobileinhaler AT abdeltawabm pharmacokineticsandpharmacodynamicsofmoistinhalationepinephrineusingamobileinhaler AT fuhru pharmacokineticsandpharmacodynamicsofmoistinhalationepinephrineusingamobileinhaler |